A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 110, Issue 2, 2008, Pages 309-315

  Garin, August ^a   Manikhas, Alexey ^b   Biakhov, Mikhail ^c   Chezhin, Mikhail ^b   Ivanchenko, Tatiana ^c   Krejcy, Kurt ^d   Karaseva, Vera ^b,e   Tjulandin, Sergey ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b Oncology Dispensary ^*  (Russian Federation)

^c Central Hospital   (Russian Federation)

^d Eli Lilly Regional Operations   (Austria)

^e Eli Lilly   (Russian Federation)

Author keywords

Carboplatin; Metastatic breast cancer; Pemetrexed

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PEMETREXED; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OLIGURIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VISCERAL METASTASIS; VITAMIN SUPPLEMENTATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BLOOD PLATELETS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; FEMALE; GLUTAMATES; GUANINE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 44849095110     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9722-5     Document Type: Article

References (24)

1. Calvert H (1999) An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 26(2 Suppl 6):3-10
2. Mendelsohn LG, Shih C, Chen VJ et al (1999) Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26(2 Suppl 6):42-47
3. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
4. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22(9):1589-1597
5. Gomez HL, Hanauske A-R, Santillana S et al (2002) A phase II trial of pemetrexed in previously untreated breast cancer. Breast Cancer Res Treat 76(Suppl 1):S66 (abstr)
6. Llombart-Cussac A, Theodoulou M, Rowland K et al (2006) Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous antracycline and taxane treatment: phase II study. Clin Breast Cancer 7:380-385
7. Martin M, Spielmann M, Namer M et al (2003) Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 14:1246-1252
8. Miles DW, Smith IE, Coleman RE et al (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37:1366-1371
9. O'Shaughnessey J, Liepa AM, Nguyen B (2002) Symptom improvement with pemetrexed for heavily pre-treated patients with advanced breast cancer. Breast Cancer Res Treat 76(Suppl 1):530 (abstr)
10. Ma CX, Steen P, Rowland KM et al (2006) A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Annalas of Oncology 17(2):226-231
11. Dittrich C, Petruzelka L, Vodvarka P et al (2006) A phase I study of pemetrexed (Alimta) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res 12(23):7071-7078
12. Paridaens R, Dirix L, Mellaerts N et al (2003) Phase I study of pemetrexed (Alimta) and epirubicin in patients with locally advanced or metastatic breast cancer. Proc Amer Soc Clin Oncol, 21:A290 (abstr)
13. Crown J, Pegram M (2003) Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79(Suppl 1):S11-18
14. Martin M (2001) Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2:190-208
15. Perez EA, Hillman DW, Stell PJ et al (2000) A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 88:124-131
16. Fountzilas G, Dimopoulos AM, Papadimitriou C et al (1998) First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 9:1031-1034
17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
19. National Cancer Institute (1998) Common Toxicity Criteria (version 2.0). Cited March 23
20. Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481
21. O'Shaughnessy JA, Clark RS, Blum JL et al (2005) Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6:143-149
22. Llombart-Cussac A, Martin M, Harbeck N et al (2006) Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): clinical results and exploratory pharmacogenomic analysis. J Clin Oncol 24(18S):3077 (abstr)
23. Perez EA (2004) Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9:518-527
24. Valero V, Holmes FA, Walters RS et al (1995) Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894